<DOC>
	<DOCNO>NCT00345982</DOCNO>
	<brief_summary>The purpose study determine whether addition sertindole clozapine treatment improve psychosis metabolic side-effects clozapine patient treatment-resistant schizophrenia .</brief_summary>
	<brief_title>Augmenting Clozapine With Sertindole - SERCLOZ</brief_title>
	<detailed_description>Around 20 % patient schizophrenia treatment-resistant . Clozapine still drug choice patient 2/3 respond adequately clozapine . In study clozapine treatment augment sertindole . Patients randomize either clozapine sertindole 12 week continue open-label study sertindole 12 week . The purpose open-label study determine whether clozapine dosage reduce due addition sertindole .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Clozapine</mesh_term>
	<mesh_term>Sertindole</mesh_term>
	<criteria>ICD10 diagnosis schizophrenia ( F20.03 ) Clozapine treatment minimum 6 month Total PANSS &gt; 65 No antipsychotic clozapine drug 1 month prior inclusion QTc &gt; 500 m Violence SPC clozapine Serdolect Major depression Significant substance misuse interfere participate study Cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Treatment-resistant</keyword>
	<keyword>sertindole</keyword>
	<keyword>clozapine</keyword>
</DOC>